NorgesInvestor
Founded in 1996, NorgesInvestor is an Oslo-based asset management firm focused on strategic and financial value creation. It engages in private equity investments, discretionary wealth management, listed securities investments, and private equity secondaries across sectors such as telecommunications, information technology, retail, alternative energy, oil service, technology, and manufacturing.
Top Stages
1 past transactions
Algeta
Series A in 2005
Algeta ASA is an oncology company headquartered in Oslo, Norway, that specializes in developing targeted therapies for cancer treatment using its proprietary alpha-pharmaceutical platform. Founded in 1997, the company focuses on fulfilling unmet medical needs in cancer care. Its lead product, radium-223 dichloride, has successfully completed Phase III clinical trials for treating castration-resistant prostate cancer with bone metastases. Additionally, Algeta is advancing its research on thorium-227, an alpha-emitter that is in the preclinical phase and is being developed in conjunction with tumor-targeting molecules to create targeted thorium conjugates. The company has a collaboration agreement with Bayer Pharma AG for the global development and commercialization of radium-223. Algeta was previously known as Anticancer Therapeutic Inventions AS before rebranding in 2003.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.